Перейти к содержанию

Nasus Pharma Ltd (NSRX) stock: revenue, earnings & dividend

Nasus Pharma Ltd (NSRX, NYSE): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener NSRX · NYSE Pharma & Biotech IL-

Key figures

Fiscal year
2025
Revenue
1.24 bn $
Revenue growth
–
Revenue growth 5y (p.a.)
–
Net income
-5.86 m $
Net margin
-0.5 %
Operating margin
-0.4 %
Earnings per share (diluted)
-0.72 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
5 m $
Equity
2.77 m $
Equity ratio
55.3 %
Return on equity
-211.6 %
Cash
1.24 m $
Operating cash flow
-4.92 m $
Free cash flow
-4.93 m $
Shares outstanding
9,015,383

History

Revenue by fiscal year

2025 1.24 bn $

Net income by fiscal year

2023 -1.05 m $
2024 -1.53 m $
2025 -5.86 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20251.24 bn $-5.86 m $-0.72 $–-4.92 m $
2024–-1.53 m $-0.22 $–-665,000 $
2023–-1.05 m $-0.20 $–-1.03 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)